Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab for Severe Hypereosinophilic Syndrome (Study 200622)
2014-001232-11Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Mepolizumab with Placebo (2 arms). Primary endpoint: Proportion of subjects with HES flare. Started Sep 2016; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2014-001232-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001232-11.